|
|
Volumn 89, Issue 2 SUPPL. 1, 2002, Pages 18-25
|
|
From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA TOCOPHEROL;
ANGIOTENSIN 2 RECEPTOR ANTAGONIST;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
RAMIPRIL;
TELMISARTAN;
VALSARTAN;
ATHEROSCLEROSIS;
BLOOD PRESSURE REGULATION;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONGESTIVE HEART FAILURE;
CORONARY ARTERY DISEASE;
DEATH;
DEMENTIA;
DIABETES MELLITUS;
DRUG TOLERABILITY;
HEART ATRIUM FIBRILLATION;
HEART EJECTION FRACTION;
HEART FAILURE;
HEART INFARCTION;
HEART LEFT VENTRICLE FAILURE;
HORMONE ACTION;
HOSPITALIZATION;
HUMAN;
KIDNEY DISEASE;
MORTALITY;
PERIPHERAL VASCULAR DISEASE;
PRIORITY JOURNAL;
PROGNOSIS;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
STROKE;
|
|
EID: 0037165243
PISSN: 00029149
EISSN: None
Source Type: Journal
DOI: 10.1016/S0002-9149(01)02323-2 Document Type: Conference Paper |
|
Times cited : (163)
|
|
References (0)
|
